Stuart Orkin
Stuart H. Orkin | |
|---|---|
| Born | April 23, 1946 Manhattan, New York, U.S. |
| Alma mater | Massachusetts Institute of Technology (B.S.) Harvard Medical School (M.D.) |
| Known for | Molecular genetics of blood disorders; GATA transcription factors; BCL11A and fetal hemoglobin regulation; CRISPR/Cas9 gene editing therapy (Casgevy) for sickle cell disease |
| Awards | E. Mead Johnson Award (1987) Warren Alpert Foundation Prize (1993) Jessie Stevenson Kovalenko Medal (2013) William Allan Award (2014) George M. Kober Medal (2018) Nemmers Prize (2018) King Faisal Prize (2020) Gruber Prize in Genetics (2021) Canada Gairdner International Award (2022) Shaw Prize (2024) |
| Scientific career | |
| Fields | Hematology, Pediatric oncology, Stem cell biology |
| Institutions | Boston Children's Hospital Dana–Farber Cancer Institute Harvard Medical School |
| Academic advisors | Philip Leder |
| Notable students | Jean-Pierre Bourquin |
Stuart Holland Orkin (born April 23, 1946) is an American physician-scientist specializing in hematology, pediatric oncology, and stem cell biology. He is the David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School and an Investigator of the Howard Hughes Medical Institute (HHMI) at Boston Children's Hospital. Orkin is known for defining the molecular basis of human blood disorders, discovering key hematopoietic transcription factors, and pioneering gene therapy and gene editing approaches for sickle cell disease and thalassemia. He is a member of the National Academy of Sciences and the Institute of Medicine.